Cleared Traditional

K182038 - URiSCAN 10ACR urine strips on the URiSCAN Optima urine analyzer (FDA 510(k) Clearance)

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K182038 · Yd Diagnostics Corporation · Chemistry device
Dec 2018
Decision
133d
Days
Class 2
Risk

K182038 is an FDA 510(k) clearance for the URiSCAN 10ACR urine strips on the URiSCAN Optima urine analyzer. Classified as Enzymatic Method, Creatinine (product code JFY), Class II - Special Controls.

Submitted by Yd Diagnostics Corporation (Yongin-Si, KR). The FDA issued a Cleared decision on December 10, 2018 after a review of 133 days - within the typical 510(k) review window.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1225 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

Submission Details

510(k) Number K182038 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 30, 2018
Decision Date December 10, 2018
Days to Decision 133 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Statement
Regulatory Context
Review time vs. panel average
101d faster than avg
Panel avg: 234d · This submission: 133d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JFY Enzymatic Method, Creatinine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1225
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.